Toxic epidermal necrolysis after the administration of enfortumab vedotin for urinary bladder urothelial carcinoma

INTRODUCTION: Enfortumab vedotin is a novel drug for locally advanced or metastatic urothelial carcinoma, but it is associated with a high incidence of skin reactions (up to 47.0%). CASE PRESENTATION: A 71‐year‐old male was administered enfortumab vedotin for bladder cancer associated with lymph nod...

Descripción completa

Detalles Bibliográficos
Autores principales: Mimura, Yuji, Kobayashi, Aya, Utazu, Haruhiko, Matsumoto, Yuki, Mizusawa, Hiroya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9978062/
https://www.ncbi.nlm.nih.gov/pubmed/36874989
http://dx.doi.org/10.1002/iju5.12562

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9978062/
https://www.ncbi.nlm.nih.gov/pubmed/36874989
http://dx.doi.org/10.1002/iju5.12562

Ejemplares similares